65058-52-8

Basic information

• Product Name: (1S)-1-Phenyl-2-(methylamino)ethanol
• Synonyms: (1S)-1-Phenyl-2-(methylamino)ethanol;[S,(+)]-α-[(Methylamino)methyl]benzyl alcohol
• CAS NO: 65058-52-8
• Molecular Formula: C₉H₁₃NO
• Molecular Weight: 151.21
• Mol File: 65058-52-8.mol
• Article Data: 11

Chemical Properties

• Melting Point: 45-47 °C
• Boiling Point: 244.1±7.0 °C(Predicted)
• Appearance: /
• Density: 1.036±0.06 g/cm3(Predicted)
• PKA: 14.03±0.20(Predicted)
• CAS DataBase Reference: (1S)-1-Phenyl-2-(methylamino)ethanol(CAS DataBase Reference)
• NIST Chemistry Reference: (1S)-1-Phenyl-2-(methylamino)ethanol(65058-52-8)
• EPA Substance Registry System: (1S)-1-Phenyl-2-(methylamino)ethanol(65058-52-8)

Safety Data

• Hazardous Substances Data: 65058-52-8(Hazardous Substances Data)

Usage

Description

(1S)-1-Phenyl-2-(methylamino)ethanol, commonly known as methamphetamine, is a psychoactive drug that acts as a stimulant on the central nervous system. It is a Schedule II controlled substance in the United States due to its high potential for abuse and dependence.

Uses

Used in Pharmaceutical Industry:
(1S)-1-Phenyl-2-(methylamino)ethanol is used as a prescription medication for the treatment of attention deficit hyperactivity disorder (ADHD) and obesity. It helps to increase focus, attention, and energy levels in individuals with these conditions.
Used in Recreational Drug Use:
Methamphetamine is used recreationally for its euphoric and energizing effects. However, its widespread illicit production and distribution have led to significant public health and safety concerns, including addiction, overdose, and negative impacts on communities.
Note: It is important to emphasize that the recreational use of methamphetamine is illegal and highly dangerous, leading to severe health risks and social consequences. The information provided here is for educational purposes only and does not endorse or promote the misuse of this substance.

Upstream product

• 33350-26-4 2-(N-benzyl-N-methylamino)acetophenone 
• 35534-19-1 2-(methylamino)-1-phenylethan-1-one 
• 70-11-1 α-bromoacetophenone 
• 68579-60-2 2-(methylamino)-1-phenylethanol 
• 108-05-4 vinyl acetate 
• 96-09-3 styrene oxide 
• 2549-14-6 (R)-2-Amino-1-phenylethanol 
• 10020-96-9 (R)-Mandelonitrile 
• 70111-05-6 (S)-2-chloro-1-phenylethanol 
• 913289-34-6 Methyl-carbamic acid (S)-2-chloro-1-phenyl-ethyl ester 
• 23826-47-3 2-(methylamino)-1-phenylethanone hydrochloride 
• 20780-54-5 (S)-styrene oxide 
• 74-89-5 methylamine 
• 913289-36-8 (5S)-3-methyl-5-phenyl-2-oxazolidinone 

Downstream Products

• 556025-36-6 N-(4-fluorobenzyl)-9-{[[(2S)-2-hydroxy-2-phenylethyl](methyl)amino]methyl}-1-methyl-2,7-dioxo-2,3-dihydro-1H,7H-pyrido[1,2,3-de]quinoxaline-6-carboxamide 
• 556025-19-5 N-(4-chlorobenzyl)-9-{[[(2S)-2-hydroxy-2-phenylethyl](methyl)amino]methyl}-1-methyl-2,7-dioxo-2,3-dihydro-1H,7H-pyrido[1,2,3-de]quinoxaline-6-carboxamide 
• 573987-69-6 (5R)-2-chloro-3-methyl-5-phenyl-1,3,2-oxazaphospholidine 
• 672326-29-3 N-(4-chlorobenzyl)-2-((((2S)-2-hydroxy-2-phenylethyl)(methyl)amino)methyl)-4-oxo-7-(2-(tetrahydro-2H-pyran-2-yloxy)ethyl)-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide 
• 672326-28-2 N-(4-chlorobenzyl)-2-((((2S)-2-hydroxy-2-phenylethyl)(methyl)amino)methyl)-4-oxo-7-(3-(tetrahydro-2H-pyran-2-yloxy)propyl)-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide 
• 672326-26-0 N-(4-chlorobenzyl)-7-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-2-((((2S)-2-hydroxy-2-phenylethyl)(methyl)amino)methyl)-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide 
• 56030-50-3 (+)-(R)-1-phenyl-N-methyl-7,8-dimethoxy-1,2,4,5-tetrahydro-3H-benzazepine 
• 125629-50-7 (+)-(S)-N-(3,5-dimethoxyphenethyl)halostachine 
• 434937-32-3 N⁶-benzoyl-5'-O-[bis(4-methoxyphenyl)(phenyl)methyl]-3'-O-[(2S,5S)-3-methyl-5-phenyl-1,3,2-oxazaphospholidin-2-yl]-2'-deoxyadenosine 
• 434937-33-4 N⁴-benzoyl-5'-O-[bis(4-methoxyphenyl)(phenyl)methyl]-3'-O-[(2S,5S)-3-methyl-5-phenyl-1,3,2-oxazaphospholidin-2-yl]-2'-deoxycytidine 
• 434937-31-2 5'-O-[bis(4-methoxyphenyl)(phenyl)methyl]-3'-O-[(2S,5S)-3-methyl-5-phenyl-1,3,2-oxazaphospholidin-2-yl]thymidine 

Relevant articles and documents

Method for synthesizing chiral alpha-amino alcohol compound

The invention discloses a method for synthesizing a chiral alpha-amino alcohol compound. The method comprises the following steps: sequentially adding an iron catalyst, a ligand, ketone, an organic solvent and silane into a reaction system at 20-30 DEG C in a nitrogen atmosphere, then stirring the obtained mixture, and carrying out column chromatography separation on the obtained product to obtain a product, namely chiral alpha-amino alcohol. According to the invention, the most high-yield iron catalyst in earth crust is used, and cheap silane (PMHS, 500 g/298 yuan) is adopted as a reducing agent, so the asymmetric reduction reaction of alpha-amino ketone can be efficiently achieved under mild conditions so as to obtain the high-yield optically-active chiral alpha-amino alcohol compound; and moreover, through the creative labor of the inventor, reaction yield can reach 99%, and meanwhile, the content of the target product in the generated reaction product is 99%.

Optimization of immobilization conditions of Mucor miehei lipase onto Florisil via polysuccinimide spacer arm using response surface methodology and application of immobilized lipase in asymmetric acylation of 2-amino-1-phenylethanols

In this study, the immobilization of Mucor miehei lipase onto Florisil support via polysuccinimide spacer arm was scrutinized by using a 3-factor and 3-level Box-Behnken design. The independent parameters were immobilization pH, immobilization time and initial lipase concentration and the response was the specific activity of immobilized lipase. A quadratic equation was used to explain the relationship between the response and independent parameters. After analysis of variance test, coefficient of determination and adjusted coefficient of determination values were estimated as 0.98 and 0.94, respectively. The optimal immobilization pH, immobilization time and initial lipase concentration were determined as 6.0, 7 h and 1.1 mg mL-1, respectively, after desirability analysis. The specific activity values for three individual experiments were observed as 25.88 ± 0.73, 26.06 ± 0.47 and 25.96 ± 0.52 U mg protein-1 under the optimized conditions. The hydrolytic activities of free and immobilized lipase preparations were characterized using p-nitrophenyl palmitate as substrate. The esterification activity of immobilized lipase preparation was evaluated by asymmetric acylation of 2-(methylamino)-1-phenylethanol, 2-(ethylamino)-1- phenylethanol, 2-(butylamino)-1-phenylethanol, and 2-(hexylamino)-1- phenylethanol with vinyl acetate. The acylation protocol was optimized in terms of the effects of initial water amount, reaction temperature, molar ratio of amino alcohol to vinyl acetate, biocatalyst loading, organic medium and kind of lipases used. The developed protocol provided a facile methodology for the preparation of enantiopure 2-amino-1-phenylethanols which may be used as potential new β-adrenergic receptor antagonists.

Design and synthesis of substituted 4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-2-carboxamides, novel HIV-1 integrase inhibitors

A series of 4-oxo-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine-2-carboxamides was synthesized and tested for their inhibition of HIV-1 integrase catalytic activity and HIV-1 replication in cells. Structure-activity studies around lead compound 5 indicated that a coplanar relationship of metal-binding heteroatoms provides optimal binding to the integrase active site. Identification of potency-enhancing substituents and adjustments in lipophilicity provided 17b which inhibits integrase-catalyzed strand transfer with an IC50 value of 74 nM and inhibits HIV-1 replication in cell culture in the presence of 50% normal human serum with an IC95 value of 63 nM.